Assessing the effectiveness of recombinant Aujeszky's disease vaccine strain YS-400 in swine

摘要

Aujeszky's disease virus (ADV) causes Aujeszky's disease (AD), which economically impacts the swine industry. Although AD is distributed worldwide, several countries, including Denmark, England, Mexico, and Germany, have been officially declared as AD-free by a national AD eradication program. The AD marker vaccine is a modified live virus with reduced virulence produced by deletions in the genes encoding thymidine kinase (TK) and glycoprotein E (gE). Although an inactivated ADV vaccine has been successfully used to control AD, an effective and safe live vaccine with a differentiating marker will be of great value in areas where the disease is endemic. In this study, we investigated the recombinant ADV strain YS-400 in terms of its safety and efficacy as a candidate marker vaccine against AD.